CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 4,440,000 shares, a decline of 21.7% from the October 31st total of 5,670,000 shares. Based on an average daily volume of 809,100 shares, the short-interest ratio is presently 5.5 days.

CytomX Therapeutics Trading Down 0.5 %

CytomX Therapeutics stock traded down $0.01 during mid-day trading on Monday, hitting $1.06. 599,889 shares of the company’s stock were exchanged, compared to its average volume of 2,456,200. CytomX Therapeutics has a 1-year low of $0.83 and a 1-year high of $5.85. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.27. The stock has a market cap of $82.56 million, a P/E ratio of 6.24 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same quarter in the prior year, the firm posted $0.04 EPS. As a group, research analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.77.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $104,000. Geode Capital Management LLC raised its stake in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 16,359 shares in the last quarter. FMR LLC boosted its holdings in shares of CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.